# US 2026/0216123 A1 · Pharmaceutical composition for preventing or treating degenerative osteoarthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216123 A1
- Document ID: US20260216123A1
- Status: Published application
- Kind: A1
- Application number: 19/146,639
- Filed: 2024-01-05
- Published: 2026-07-30
- Earliest claimed: 2023-01-12
- Assignees: Glaceum Inc.
- Applicants: Glaceum Inc.
- Inventors: Sang Ku YOO; Hyung Soon PARK; Tae Won KIM; Hyeong Min LEE; Hyun Ju JEON; Leo Sungwong CHOI
- Web page: https://patentgrep.com/patent/US20260216123A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for preventing or treating degenerative arthritis, containing a pyrano[2,3-f]chromene derivative compound, a pharmaceutically acceptable salt thereof, or a solvate thereof.

## Claims

### Claim 1

A method for preventing or treating degenerative osteoarthritis in a subject in need thereof, comprising administering to the subject a pyrano[2,3-f]chromene derivative compound of Formula 1 below, a pharmaceutically acceptable salt thereof, or a solvate thereof:
wherein
R1 is a hydrogen atom, a substituted or unsubstituted linear or branched C1-C6 alkyl group, a halogen atom, a substituted or unsubstituted linear or branched C1-C6 alkoxy group, or a substituted or unsubstituted linear or branched C1-C4 thioalkyl group;
R2 is a hydrogen atom, methyl, ethyl, methoxy or ethoxy; and
R3 and R4 are each independently a hydrogen atom or a C1-C2 alkyl group,
wherein the substituents of the substituted alkyl, the substituted alkoxy and the substituted thioalkyl are each independently a linear or branched C1-C5 alkyl group, a halogen atom, a linear or branched C1-C5 alkoxy group, or a linear or branched C1-C3 thioalkyl group.

### Claim 2 (depends on 1)

The method of claim 1, wherein
R1 is ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-methylpropoxy, n-pentoxy, 2-methylbutoxy, 3-methylbutoxy, 2-ethylpropoxy, n-hexyloxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, or 2-ethylbutoxy,
R2 is a hydrogen atom, and
R3 and R4 are each independently methyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound represented by Formula 1 comprises any one of the following compounds:

### Claim 4 (depends on 1)

The method of claim 1, wherein the degenerative osteoarthritis is primary osteoarthritis or secondary osteoarthritis.

### Claim 5 (depends on 4)

The method of claim 4, wherein the primary osteoarthritis is idiopathic osteoarthritis.

### Claim 6 (depends on 4)

The method of claim 4, wherein the secondary osteoarthritis is chondromalacia patella or patellofemoral degenerative arthritis secondary to primary osteoarthritis.
